HCM

SEC filing HCM Presents Savolitinib Phase II Data Showing 32.3% ORR, 9.7 Months Median DoR in MET-Amplified Gastric Cancer at Upcoming ASCO Meeting

11d ago

SEC filing HCM Gets NMPA Approval for ELUNATE Combo Therapy, 63% Reduced Disease Progression Risk, 22.2 Months Median PFS in FRUSICA-2 Trial

12d ago

News Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

14d ago

SEC filing HCM Reports $0 Revenue, $0 EPS, No Growth, No Deal

54d ago

SEC filing HCM Vesting 19,913 Shares, Dr Weiguo Su CEO, LTIP Awards, US$0.10 Ordinary Shares, KYG4672N1016 ISIN

78d ago

SEC filing HCM Vesting of LTIP Awards: Dr Su 524,079 Shares, Mr Cheng 202,238 Shares, Total 726,317 Shares

83d ago

SEC filing HCM Announces Prof Mok Retirement, Appoints Dr Bhatia as Lead Independent Director, Dr Hu as Tech Committee Chair, Prof Tan to Sustainability Committee

88d ago

Scanner Unusual volume (1.3x average)

118d ago

News HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

139d ago

News HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

145d ago

News HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

148d ago

News HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

153d ago

News BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

165d ago